How well does pomalidomide work with other medications?

Pomalidomide is an immunomodulatory drug mainly used to treat hematological malignancies such as relapsed/refractory multiple myeloma. In recent years, the combination of pomalidomide and other drugs has achieved remarkable results in clinical practice and has become one of the important options for the treatment of multiple myeloma.

The combination of pomalidomide and dexamethasone is one of the most common regimens. This combined treatment regimen not only improved the patient's objective response rate, but also prolonged the patient's progression-free survival and overall survival. In addition, pomalidomide combined with dexamethasone can also reduce patients' resistance to immunomodulatory drugs such as lenalidomide, providing a new treatment option for patients with relapsed/refractory multiple myeloma.

In addition to dexamethasone, pomalidomide can also be used in combination with a variety of other drugs, such as bortezomib, cyclophosphamide, etc. These combination treatment regimens have also shown good efficacy and safety in clinical trials. For example, the three-drug combination of pomalidomide, bortezomib, and dexamethasone can significantly improve the patient's objective response rate and prolong progression-free survival when treating multiple myeloma, and it also shows good efficacy in patients with renal impairment.

However, while pomalidomide combination therapy brings curative effects, it is also necessary to pay attention to its possible adverse events. In particular, hematological adverse events, such as anemia, thrombocytopenia, and neutropenia, are common adverse reactions in pomalidomide combination therapy. Therefore, during clinical use, it is necessary to closely monitor the patient's blood routine and other indicators, adjust the drug dosage in a timely manner or take necessary intervention measures to ensure the patient's treatment safety.

Overall, pomalidomide in combination with other drugs has shown good efficacy and safety in the treatment of hematological malignancies such as multiple myeloma. However, it is still necessary to pay attention to the adverse reactions and side effects of drugs during clinical use to ensure the safety of patient treatment.

xa0

Reference materials:https://pubmed.ncbi.nlm.nih.gov/38421372/